{"id":"azd9833-with-capivasertib","phase":"phase_1","safety":{"commonSideEffects":[{"rate":"30%","effect":"Fatigue"},{"rate":"20%","effect":"Nausea"},{"rate":"15%","effect":"Diarrhea"}]},"status":"active","trials":["NCT03616587"],"aliases":[],"patents":[],"pricing":[],"timeline":[],"aiSummary":"AZD9833 is a CDK4/6 inhibitor, and capivasertib is a pan-PI3K inhibitor. Used for Breast cancer.","brandName":"AZD9833 with capivasertib","companyId":"astrazeneca","mechanism":{"_ai_source":"groq-llama-8b","explanation":"AZD9833 works by inhibiting the CDK4/6 pathway, while capivasertib targets the PI3K pathway. This combination may help treat certain types of cancer.","oneSentence":"AZD9833 is a CDK4/6 inhibitor, and capivasertib is a pan-PI3K inhibitor.","_ai_confidence":"medium"},"commercial":null,"companyName":"AstraZeneca","competitors":[],"genericName":"AZD9833 with capivasertib","indications":{"approved":[{"name":"Breast cancer"}]},"labelChanges":[],"trialDetails":[],"manufacturing":[],"administration":{"icon":"","route":"","frequency":"","formulation":""},"formularyStatus":[],"apiManufacturers":[],"developmentCodes":[],"ownershipHistory":[],"biosimilarFilings":[],"firstApprovalDate":"","companionDiagnostics":[],"firstApprovalCountry":null,"rwe":[],"genericFilers":[],"relatedDrugs":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"modality":"Small molecule","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":false,"score":3}}